## OTHER POTENTIAL CONDITIONS:

Epidemiology

This provides suggestions as you engage in shared health care decision-making with Veterans. It is not intended to replace clinical judgement.

Given evidence that COVID-19 may increase the risk for Diabetes, renal impairment, cardiovascular complications and autoimmune conditions, a history of infection should be considered along with other factors in deciding who should be screened for these conditions.

| Cardiovascular  |  |
|---|--|
| Increased risk of myocardial infarction (MI),<br>cardiovascular accident (CVA), congestive heart<br>failure (CHF), myocarditis <sup>35</sup> (Xie Y, 2022)  | <ul> <li>High awareness for <u>cardiovascular complications</u><sup>36</sup><br/>(Gluckman T, 2022)</li> </ul>   |
| Kidney Disease  |  |
| Increased risk of significant decline in estimated glomerular filtration rate (eGFR), proportional to severity of disease, though present even in those not admitted to the hospital <sup>37</sup> (Bowe B, 2021)   | <ul> <li>If not already assessed, evaluate kidney function glomerular filtration rate (GFR) using creatine or cystatin C at 3-6 months after resolution of COVID-19</li> <li>Compare results to pre-COVID-19 GFR if available</li> </ul>   |
| Diabetes  |  |
| Compared with those who never had COVID-19,<br>Veterans who have had COVID-19 are at greater<br>risk of developing type 2 Diabetes up to a year later,<br>even after a mild SARS-CoV-2 infection. <sup>38</sup> (Xie Y,<br>2022) <sup>39</sup> (Wander P, 2022)   | <ul> <li>Ask all Veterans who had severe COVID-19 about signs and symptoms of diabetes at every routine visit. Consider asking Veterans who had mild or asymptomatic COVID-19.</li> <li>A baseline A1c test should be done post-COVID-19 for all Veterans</li> <li>For symptomatic Veterans:         <ul> <li>Veterans experiencing post-COVID-19 signs and symptoms with pre-existing diabetes should have an additional A1c test at 6 months post-infection</li> <li>Veterans experiencing post-COVID-19 signs and symptoms without pre-diabetes but with significant risk factors for diabetes- such as strong family history and obesity-can be considered for an A1c test at 6 months post-infection</li> <li>Routine laboratory testing for other indications should include a Fasting Blood Glucose (FBS) when possible</li> <li>If there has been a significant increase (&gt;0.5%) in A1c from baseline, obtain a repeat A1c or FBS earlier than 6 months post-infection</li> </ul> </li> </ul> |
| Autoimmune  |  |
| Up to 25% may develop antinuclear antibody (ANA) positivity, but the titers were low and deemed not clinically significant. <sup>40</sup> (Lerma L, 2020) The serology of 61 patients 5 weeks after COVID-19 had no increased incidence of anti-cyclic citrullinated peptides (CCP) positivity. <sup>41</sup> (Derksen V, 2021) | <ul> <li>Coronaviruses seem to typically cause signs and symptoms of arthralgia and myalgia. <sup>42</sup> (Zacharias H, 2021) <sup>43</sup> (Cui D, 2022) If a patient develops clinical features of inflammatory arthritis following COVID-19, the diagnostic work-up should be similar to a patient with new onset rheumatoid arthritis (RA) in an infection naive patient. <sup>44</sup> (Sapkota H, 2022)</li> </ul>  |

<sup>35</sup> Xie Y. Long-term cardiovascular outcomes of COVID-19. Nat Med 28, 583–590 (2022). https://doi.org/10.1038/s41591-022-01689-3

<sup>36</sup> Gluckman. ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults, 2022. doi: 10.1016/j.jacc.2022.02.003

9, Issue 6, June 2022, ofac170, https://doi.org/10.1093/ofid/ofac170

<sup>&</sup>lt;sup>37</sup> Bowe B. JASN November 2021, 32 (11) 2851-2862; DOI: https://doi.org/10.1681/ASN.2021060734

<sup>&</sup>lt;sup>38</sup> Xie Y. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022 May;10(5):311-321. doi: 10.1016/S2213-8587(22)00044-4

<sup>&</sup>lt;sup>39</sup> Wander P. The Incidence of Diabetes Among 2,777,768 Veterans with and Without Recent SARS-CoV-2 Infection. Diabetes Care 1 April 2022; 45 (4): 782–788. https://doi.org/10.2337/dc21-1686

<sup>&</sup>lt;sup>40</sup> Lerma L. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun, 2020. 10.1016/j.jtauto.2020.100073

<sup>&</sup>lt;sup>41</sup> Derksen V. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis, 2021. http://dx.doi.org/10.1136/annrheumdis-2021-219859 <sup>42</sup> Zacharias H. Rheumatological complications of Covid 19. Autoimmun Rev, 2021. 20(9): 10.1016/j.autrev.2021.102883

<sup>&</sup>lt;sup>43</sup> Cui D. Rheumatic Symptoms Following Coronavirus Disease 2019 (COVID-19): A Chronic Post–COVID-19 Condition, Open Forum Infectious Diseases, Volume

<sup>&</sup>lt;sup>44</sup> Sapkota H. Long COVID from rheumatology perspective - a narrative review. Clin Rheumatol, 2022. 41(2): p. 337-348. 10.1007/s10067-021-06001-1